Results 121 to 130 of about 6,465,161 (268)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Median Progression-free and Overall Survival.

, 2016
Median Progression-free and Overall Survival.
Nick Pavlakis (783392), David L. Chan (783391), Sumit Lumba (3161073), Stephen J. Clarke (3161076), Matthew H. Wong (3161064), Jaswinder Samra (3161070), Adrian Lee (3161067), Bob T. Li (843151)   +7 more
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Comparison of disease free survival in breast cancer molecular subtypes [PDF]

Caspian Journal of Internal Medicine
Background: Breast cancer management depends on molecular subtypes. The aim was to compare disease-free survival (DFS) among the different subgroups. Overall survival (OS) is a secondary endpoint.
Maryam Esmati, Fatemeh Monfaredi, Mohsen Vakili Sadeghi, Mohammad Ranaee, Hossein ghorbani, Sadegh Sedaghat, Hemmat Gholinia   +6 more
doaj  

Progression-free survival curve of the statin and non-statin cohorts in patients with EGFR-TKIs lung cancer.

, 2017
Progression-free survival curve of the statin and non-statin cohorts in patients with EGFR-TKIs lung cancer.
Chuan-Pin Lee (3716623), Ru-Jiun Huang (3716620), Ying-Huang Tsai (244430), I-Chuan Chen (3160896), Ming-Szu Hung (246305), Pau-Chung Chen (130563), Yao-Hsu Yang (441809)   +6 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Progression-free survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.

, 2016
Progression-free survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.
Lisa Derosa (2605687), Cristian Lolli (3150675), Emanuela Scarpi (382324), Orazio Caffo (3150690), Sunnya Zarif (3150678), Vincenza Conteduca (3150663), Gianmauro Numico (591004), Francesco Massari (295545), Tony Elliott (3150687), Robert J. Jones (3150666), Paolo Fabbri (3150681), Catherine Hanna (3150669), Helen Joyce (3150672), Simon J. Crabb (1923172), Ugo De Giorgi (2605693), Francesca Maines (3150684)   +15 more
core   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Factors associated with progression-free survival.

, 2018
Factors associated with progression-free survival.
Jennifer Dumoulin (5131088), Thierry Chinet (531664), Etienne Giroux Leprieur (5131082), Marie-Ange Massiani (5131085), Sylvie Labrune (5131073), Violaine Giraud (5131079), Coraline Dumenil (5131076)   +6 more
core   +1 more source